http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020005068-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ddcf2c315c108125b002b152dccca9cb |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2019-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d380e4c557c953ee2f8a4797a34f0cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44a2b865b1d2ee1afde59b3ac63ad0e6 |
| publicationDate | 2020-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020005068-A2 |
| titleOfInvention | Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof |
| abstract | The present invention relates to the field of cancer, more particularly to the field of immunotherapy and gene signatures. Provided are two specific and distinct gene signatures, namely a Response Immune Signal (RIS) gene signature and a Stromal Immune Signal (SIS) gene signature, which can be used as biomarkers to accurately predict the response of a cancer subject to treatment with a PD-1 antagonist (e.g., PD-1 antibody) and/or a CTLA-4 antagonist (e.g., CTLA-4 antibody). In particular, it was found that the RIS and SIS gene signatures of the invention may be used in combination to predict the response of a cancer subject to treatment with a combination therapy consisting of a PD-1 antagonist (e.g., PD-1 antibody) and a CTLA-4 antagonist (e.g., CTLA-4 antibody). The gene signatures of the invention may be advantageously used in methods for treating cancer, such as melanoma, and to help devise treatment strategies best suited to individual patients (e.g., to achieve personalized therapy, and spare patients from undesired side effects, e.g., toxicity). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021228888-A1 |
| priorityDate | 2018-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 137.